BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 9557291)

  • 1. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between diversity of hepatitis C virus quasispecies and viremia, activity of liver disease and response to interferon therapy].
    Tang X; Qian K; Yuan X; Johnson YN
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):128-31. PubMed ID: 12196822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients.
    Neau D; Jouvencel AC; Legrand E; Trimoulet P; Galperine T; Chitty I; Ventura M; Le Bail B; Morlat P; Lacut JY; Ragnaud JM; Dupon M; Fleury H; Lafon ME
    J Med Virol; 2003 Sep; 71(1):41-8. PubMed ID: 12858407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.
    González-Peralta RP; Qian K; She JY; Davis GL; Ohno T; Mizokami M; Lau JY
    J Med Virol; 1996 Jul; 49(3):242-7. PubMed ID: 8818972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus.
    Kato T; Mizokami M; Nakano T; Orito E; Ohba K; Kondo Y; Tanaka Y; Ueda R; Mukaide M; Fujita K; Yasuda K; Iino S
    J Med Virol; 1998 Jun; 55(2):109-17. PubMed ID: 9598930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic variation characteristics of the envelope region of hepatitis C virus in the patients with chronic hepatitis].
    Chen S; Wang Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):219-22. PubMed ID: 12665923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E2 quasispecies specificity of hepatitis C virus association with allografts immediately after liver transplantation.
    Hughes MG; Rudy CK; Chong TW; Smith RL; Evans HL; Iezzoni JC; Sawyer RG; Pruett TL
    Liver Transpl; 2004 Feb; 10(2):208-16. PubMed ID: 14762858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolutionary study of hepatitis C virus envelope genes during primary infection.
    Chen S; Wang YM
    Chin Med J (Engl); 2007 Dec; 120(24):2174-80. PubMed ID: 18167197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
    Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy.
    Zeuzem S
    Forum (Genova); 2000; 10(1):32-42. PubMed ID: 10717256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease.
    Brambilla S; Bellati G; Asti M; Lisa A; Candusso ME; D'Amico M; Grassi G; Giacca M; Franchini A; Bruno S; Ideo G; Mondelli MU; Silini EM
    Hepatology; 1998 Jun; 27(6):1678-86. PubMed ID: 9620342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus.
    Lee JH; Teuber G; von Wagner M; Roth WK; Zeuzem S
    J Med Virol; 2000 Mar; 60(3):264-8. PubMed ID: 10630957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear associated with virus persistence independently of liver disease.
    Brunetto MR; Suzuki T; Aizaky H; Flichman D; Colombatto P; Abate ML; Oliveri F; Matsuura Y; Bonino F; Miyamura T
    Ital J Gastroenterol; 1996 Dec; 28(9):499-504. PubMed ID: 9131394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and therapeutic implications of hepatitis C virus compartmentalization.
    Di Liberto G; Roque-Afonso AM; Kara R; Ducoulombier D; Fallot G; Samuel D; Feray C
    Gastroenterology; 2006 Jul; 131(1):76-84. PubMed ID: 16831592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.